Table 3 Dosimetric baseline characteristics of patients who developed RP
Variable | RTOG | CTCAE | |||||
|---|---|---|---|---|---|---|---|
No RP n = 26 (%) | Pneumonitis n = 11 (%) | P value | No RP n = 22 (%) | Pneumonitis n = 15 (%) | P value | ||
GTV (cm3) | 0–99.9 | 16 (61.5) | 4 (36.4) | 0.078 | 13 (59.1) | 6 (40) | 0.324 |
≥100 | 10 (38.5) | 7 (63.6) | 9 (40.9) | 9 (60) | |||
PTV | 0–349.9 | 19 (73.1) | 4 (36.4) | 0.013 | 16 (72.3) | 6 (40) | 0.086 |
≥350 | 7 (26.9) | 7 (63.6) | 6 (27.3) | 9 (60) | |||
V 5 (%) | 0–64.9 | 13 (50) | 8 (72.7) | 0.284 | 11 (50) | 10 (66.7) | 0.50 |
≥65 | 13 (50) | 3 (27.3) | 11 (50) | 5 (33.3) | |||
V 20 (%) | 0–34.9 | 4 (15.4) | 3 (27.3) | 0.648 | 4 (18.2) | 3 (20) | 0.999 |
≥35 | 22 (84.6) | 8 (72.7) | 18 (81.8) | 12 (80) | |||
MLD (Gy) | 0–19.9 | 10 (38.5) | 5 (45.5) | 0.727 | 9 (40.1) | 7 (46.7) | 0.748 |
≥20 | 16 (61.5) | 6 (54.5) | 13 (59.1) | 8 (53.3) | |||